Zein ASSAD (France)
Robert Debré University Hospital
Department of General Pediatrics, Pediatric Infectious Disease and Internal Medicine
Dr Zein ASSAD is a pediatric infectious diseases specialist, practicing at the Infectious Diseases Team of Robert Debré University Hospital in Paris. He has achieved a master’s degree in Public Health with specialization in Infectious Risks at Institut Pasteur in Paris. During his research project for the master’s in Public Health, he used the methodology of interrupted time-series analysis to assess the impact of PCV13 implementation on the incidence of acute chest syndrome in children with sickle-cell disease. He has a real interest in the challenges of implementing preventive measures in populations at risk of severe infections such as pneumococcal diseases. He plans to carry on with a PhD in pneumococcal disease epidemiology and a postdoctoral training internship at the Sainte Justine Hospital in Montreal, with research topics focused on pneumococcus.

Presenter of 1 Presentation

 Conference Calendar

O080 - ASSOCIATION OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IMPLEMENTATION WITH THE INCIDENCE OF ACUTE CHEST SYNDROME IN CHILDREN: A TIME-SERIES ANALYSIS FROM A 13-YEAR NATIONAL SURVEILLANCE (ID 205)

Session Name
0750 - Parallel Session 10: Pneumococcal Disease and Prevention in Indigenous and Other Populations (ID 64)
Session Type
Parallel Session
Date
Wed, 22.06.2022
Session Time
15:05 - 16:35
Room
Grand Ballroom East
Presenter
Lecture Time
15:20 - 15:30

Abstract

Background

Acute chest syndrome (ACS) is a major complication of sickle-cell disease (SCD). Although Streptococcus pneumoniae is highly prevalent in children with SCD, its precise role in ACS is unclear. The impact of 13-valent pneumococcal conjugate vaccine (PCV13) implementation on ACS remains unknown. We aimed to assess the association of PCV13 implementation in the general pediatric population with the incidence of ACS in children with SCD.

Methods

We conducted an interrupted time-series analysis using an exhaustive national surveillance system. All children aged <18 years with SCD hospitalized for ACS, based on the ICD-10, between 2007 and 2019 were included. The monthly incidence of ACS per 1,000 children with SCD was analyzed by segmented linear regression with autoregressive error. We analyzed the monthly incidence of hospitalization for vaso-occlusive crisis, asthma crisis, and acute pyelonephritis per 1,000 children with SCD over the same period as control outcomes.

Results

Among the 107,694 hospitalizations of children with SCD, we included 4,007 episodes of ACS. PCV13 implementation in 2010 was associated with a significant decrease in the incidence of ACS (-0.9% per month, p=0.0007), with an estimated cumulative effect of -41.8% (95% CI [-70.8;-12.7]) by 2019. By contrast, no change was found for the three control outcomes over the study period.

Conclusions

PCV13 implementation was associated with an important reduction in the incidence of ACS in children with SCD. This vaccine benefit provides new evidence of the key role of Streptococcus pneumoniae in ACS and should be considered when estimating the impact of current and next-generation PCVs in children.

Hide